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Introduction: Primitive neuroectodermal tumors (PNETs) are rare,
rapidly progressive, small- round cell tumors with a poor prognosis
despite multimodal therapy, including surgery and chemoradiother-
apy. The treatment of choice was unknown since no clinical series
with surgical therapy had been reported. We evaluated the impact of
multimodal treatment in patients with PNETs located in the thoracic
region.
Methods: Between 1998 and 2006, 25 patients with PNETs in the
thoracic region were treated in 3 tertiary-care hospitals. The patients
consisted of 15 males and 10 females with a mean age of 27.2 years
(range, 6–60). The tumor was in the chest wall in 20 (involving the
costovertebral junction in 9), the lung in four, and the heart in
one patient. Twelve patients received neoadjuvant chemotherapy
(54.5%), and 22 of 25 patients underwent surgery.
Results: In patients who received neoadjuvant treatment, the mean
regression rate was 65.4% (range, 30–100%). Eighteen (82%) pa-
tients underwent chest wall resection, while 7 (32%) had vertebral
resections, and the remaining 4 (16%) had pulmonary resections. A
complete resection was possible in 18 of 22 patients (82%). Patients
with incomplete and complete resections had 25% and 56% 5-year
survival rates, respectively (p  0.13). The progression-free 3-year
survival rate was 36% and the median survival time was 13 months.
The complete resection rate was significantly higher in patients
receiving neoadjuvant therapy (p  0.027). The 5-year survival rate
of the patients with or without neoadjuvant therapy was 77% and
37%, respectively (p  0.22) although it prolonged the disease-free
survival (p  0.01). The 5-year survival rate of patients without
costovertebral junction involvement was 66%, whereas patients with
PNETs involving the costovertebral junction had a 21% 3-year
survival. The difference was statistically significant (p  0.01). The
5-year progression-free survival rate of patients without costoverte-
bral junction involvement was 58%, whereas patients with PNETs
involving the costovertebral junction had a 14% 1-year progression-
free survival (p  0.004).
Conclusions: PNET is an aggressive malignancy that often requires
multimodal therapy. Induction chemotherapy leads to a greater
complete resection rate and better disease-free survival, while in-
volvement of the costovertebral junction indicates a poorer survival.
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(J Thorac Oncol. 2009;4: 185–192)
Primitive neuroectodermal tumors (PNETs), from malignantsmall round cell tumors that also include Ewing sarcoma
(ES), rhabdomyosarcoma, neuroblastoma, and lymphoma,1,2
were first described by Askin et al.3 These tumors have a very
high rate of local recurrence and a propensity to metastasis4
and despite combined chemoradiotherapy plus surgery, the
prognosis is generally poor.5 Complete resection with ade-
quate margins is the goal, but too few series of patients and
survival have been reported to evaluate the role of surgical
therapy in this entity.
We report the outcome and survival of patients with
PNETs who had neoadjuvant chemoradiotherapy or surgery
alone to determine the role of neoadjuvant therapy.
PATIENTS AND METHODS
Between 1998 and 2006, 25 patients with PNETs lo-
cated in the thoracic region were treated in three institutions.
Twenty-two of the 25 patients underwent surgery. The pa-
tients comprised 15 males and 10 females with a mean age of
27.2 years (range, 6–60). Three patients (12%) underwent
chemotherapy only without surgical intervention: one patient
had complete regression with induction chemotherapy (Fig-
ure 1), one patient refused the planned surgery, and intracar-
diac involvement precluded surgical resection in one patient.
The remaining 22 patients (88%) underwent surgical resec-
tions that included thoracotomy, chest wall resection, and
pulmonary resection when needed (Table 1). Patients were
analyzed retrospectively; since this is a retrospective study,
approval of the institutional review boards was not required.
The preoperative workup included routine biochemical
tests, an electrocardiogram, basic pulmonary function tests, a
chest radiograph, and thorax computerized tomography; two
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had magnetic resonance imaging of the chest. A fiberoptic
bronchoscopy was performed in most patients. The his-
topathologic diagnosis was made via a percutaneous needle
aspiration or Tru-cut biopsy in 9 patients and an incisional
biopsy in 6 patients. In 10 patients, the definitive tissue
diagnosis was obtained at the thoracotomy despite all of the
preoperative diagnostic procedures.
The characteristics of the patients are shown in Table 1.
The primary site was the thoracic wall in 20 patients (80%),
among whom the tumor involved the costovertebral junction
in 9 (36%). The primary site was the lung in 4 (16%), and the
heart in 1 (4%). The mean diameter of the tumors was 10.2
cm (range, 1–20). None of the patients had extrathoracic
metastases.
In general, most of the patients who were known to
have PNETs before surgery were referred for neoadjuvant
therapy. Since the study was a retrospective multicenter
study, a small number of patients who were thought to have
a high likelihood of undergoing a complete resection under-
went surgical intervention directly. Twelve patients (60%)
completed the neoadjuvant therapy. The planned courses of
chemotherapy consisted of vincristine 1.4 mg/m2 of body-
surface area (maximum dose 2 mg), actinomycin D 1.5
mg/m2 per dose(substituted for doxorubicin when the total
doxorubicin dose of 375 mg/m2 was reached), and cyclophos-
phamide 1200–1800 mg/m2, followed by mesna, given to
prevent hemorrhagic cystitis caused by cyclophosphamide.
The therapy included four to eight courses and was admin-
istered every third week. The response rate was evaluated
after the fourth course. If the tumor did not respond to
chemotherapy, the patients received radiotherapy and were
operated on after the sixth course. The alternate therapy
included iphosphamide 1800 mg/m2, mesna 1800 mg/m2, and
etoposide 100 mg/m2.
A chest wall resection was performed in patients with
thoracic wall involvement. The resection was extended to
remove all of the involved chest wall structures (i.e., muscles
and fibrous tissue) when needed. The nondiseased ribs above
and below the site were also resected. Macroscopically, a
3-cm tumor-free margin lateral to the tumor was obtained
which, however, was impossible in patients with tumors
invading the costovertebral junction. In these patients, the
goal was simply a negative surgical margin. To reconstruct the
chest wall, a synthetic mesh was used if the amount of chest wall
resected was large, or the site was anterior or lateral.
Postoperatively, all tumors were confirmed pathologi-
cally to be PNETs. On pathologic examination of the biopsy
material, sheets of primitive round cells and Homer—Wright
rosettes were the principal microscopic features. Immunohis-
tochemically, the tumor cells were intensely positive for
neuron-specific enolase and the MIC-2 gene product (CD-99)
and were consistently negative for leukocyte common antigen
(CD-45), cytokeratin, smooth muscle actin, and beta human
chorionic gonadotropin. A balanced reciprocal translocation,
t(11;22) (q24;q12), was seen on chromosome analysis of the
tumor cells in the sample of patients with cardiac PNETs.
Adjuvant chemotherapy was administered in 16 pa-
tients. Postoperative adjuvant therapy could not be adminis-
tered in 6 of the 22 surgical patients (27.2%) because of poor
performance status. The mean follow-up was 32 28 months
(range, 3–108).
FIGURE 1. A, Chest magnetic res-
onance image of a patient showing
a thoracic mass that was confirmed
to be a PNET (primitive neuroecto-
dermal tumor). B, Chest computer-
ized tomography image of the
same patient taken after neoadju-
vant chemotherapy showing total
regression.
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Statistical Analysis
To compare frequencies, the 2 and Fisher exact tests
were used. The survival analysis was performed only in the
patients who had undergone surgical resection. Patient sur-
vival was expressed applying the Kaplan-Meier method using
the thoracotomy time as time zero and time of death, if it
occurred, as the end point. Differences in survival were
determined using the log-rank test. The factors affecting
survival were determined and the results were considered
significant when p  0.05.
RESULTS
All tumors in the patients given induction chemotherapy
or radiotherapy responded. A complete radiologic regression
(i.e., no lesion seen on computerized tomography) occurred in 2
patients (8%), whereas, the mean regression rate was 65.4%
(range, 30–100; Table 1).
A lobectomy was performed in 4 patients (16%; with an
additional chest wall resection in one patient), and a chest wall
resection was performed in the other 18 (84%) patients. Of these
patients, the tumor involved the costovertebral junction in seven,
and a laminectomy (n  2; 8%) or a vertebral body resection
(n  1; 4%) was performed in 3 of them. A complete resection
was achieved in 18 of the 22 surgical patients (82%). Of the
remaining four patients, the tumor originated from the costover-
tebral junction in three and the chest wall not close to the
costovertebral junction in one. No early (first 30 days) or late
(first 60 days) mortality occurred postoperatively.
Local recurrence or distant metastasis developed in 14 of
the 22 surgical patients (64%). Treatment modalities which had
been performed to these patients could be seen in Table 1.
Eighteen of 22 patients (82%) who underwent surgical
resection were reported as having complete resections. The
rate of complete resection was 100% and 64% in patients who
received induction chemotherapy followed by surgery and
surgery alone respectively. Induction chemotherapy had a
higher rate of complete resection (p  0.027).
The overall 5-year survival rate in the surgically re-
sected PNETs patients was 48% and the median survival time
was 44 months (Figure 2). Patients who had incomplete or
complete resection had 25% and 56% 5-year survival rates,
respectively (p  0.13). The mean survival time in patients
with incomplete resection was 7 months. The progression-
free 3-year survival rate in the surgically resected PNETs
patients was 36% and the median survival time was 13
months (Figure 3).
The estimated median survival time and 5-year survival
rate for patients with chest-wall tumors was 44 months and
48%, respectively. The 5-year survival rate of patients with-
out costovertebral junction involvement was 66%, whereas
patients with PNETs involving the costovertebral junction
had a 21% 3-year survival (median survival time was 7
months, Figure 4). The difference was statistically significant
(p 0.01). Patients with costovertebral junction involvement
had nearly the same survival than the pulmonary PNET
patients (3-year survival 36%; p  0.23, Figure 4). The
5-year progression-free survival rate of patients without cos-
tovertebral junction involvement was 58%, whereas patients
with PNETs involving the costovertebral junction had a 14%
1-year progression-free survival (p  0.004). Patients with
costovertebral junction involvement had a worse disease-free
survival than the pulmonary PNET patients (2-year survival
25%; p  0.3).
FIGURE 2. Overall survival curve
of the patients who underwent sur-
gical resection only.
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The 5-year survival rate of the patients with or without
neoadjuvant therapy was 77% and 37%, respectively (p 
0.22; Figure 5). The rate of locoregional recurrence and
metastasis was lower in the patients receiving neoadjuvant
chemoradiotherapy and surgery. However, the difference was
not significant (p  0.08). Neoadjuvant therapy seemed to
prolong the disease-free survival (p  0.01; Figure 6). When
analyzing the patients with complete resections, the 1-year
disease-free survival rate was 28% in patients who did not
receive neoadjuvant therapy, whereas the 5-year disease-free
survival was 57% in patients who did receive neoadjuvant
therapy (p  0.006).
Adjuvant therapy conferred no survival benefit (p 
0.4). When we analyzed the patients who underwent com-
FIGURE 3. Disease -free survival
curve of the patients who under-
went surgical resection only.
FIGURE 4. Survival curves based
on tumor location. TW, Thoracic
wall; TW  CVJ, Thoracic wall with
costovertebral junction involve-
ment.
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plete resection (R0), adjuvant therapy showed no beneficial
effect (p  0.7). Age, sex, and site of tumor were of no
importance in terms of survival.
DISCUSSION
PNETs are small round cell malign neoplasms of
neuroectodermal origin. Malignant small round cell tumors
also include rhabdomyosarcomas, neuroblastomas, and
lymphomas.1,2 The combination of a shared chromosomal
translocation (t[11;22] [q24;q12]), cellular physiology,
and clinical response has led to categorizing PNETs in the
Ewing sarcoma family of tumors. These tumors often
involve the thoracic wall, and primary pulmonary and
cardiac involvement is quite rare.1 PNETs can be differ-
FIGURE 5. Patient survival ac-
cording to the method of control:
chemotherapy (radiotherapy)
and surgery (CT(RT)S) versus
surgery (S) alone.
FIGURE 6. Disease-free survival of
patients according to the method
of control: chemotherapy (radio-
therapy) and surgery (CT(RT)S)
versus surgery (S) alone.
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entiated by characterizing the neural ultrastructure (e.g.,
neurosecretory granules, neurofilaments, and neurotu-
bules) on electron microscopy or the mmunohistochemical
expression of at least four neural markers, including CD-
99, NB-84, NSE, S-100, desmin, myogenin-MyoD1, CK,
and LCA.1,2,6,7 Approximately 90 –95% of ES/PNET are
characterized by rearrangements of the EWS gene on
22q12 and ETS-related oncogenes, most commonly FLI1
on 11q24.1
Many of the larger studies on PNETs have suggested
that these tumors are highly aggressive neoplasms that rap-
idly give rise to metastatic disease and death.1,8 The effect of
surgery in the treatment of this disease is controversial. As
seen in our series, despite complete resection and adjuvant
chemotherapy, the patients usually developed locoregional
and distant metastases.2,4,8,9 In our study, only four patients
were disease-free after multimodal treatment. In contrast, 3 of
the 11 patients with chest wall involvement had recurrences
(27.3%) despite all efforts to achieve a wide surgical resec-
tion margin, as described by others.10,11 Grier et al.11 reported
that 142 of 371 patients with a PNET or Ewing sarcoma
relapsed.
PNETs usually respond to chemotherapy,4,8–12 and pa-
tients undergoing definitive surgery after initial chemother-
apy have more successful complete resections of the tumor.10
In our series, neoadjuvant chemotherapy resulted in signifi-
cantly more complete resections. This finding has never been
reported for a series of isolated thoracic PNETs. In our study,
the patients with incomplete resections had very limited
survival and the patients who survived for a long time were
those who had wide tumor-free margins. Shamberger et al.10
concurred with this finding. Chemotherapy leads to tumor
shrinkage, which in turn allows operability with wide tumor-
free margins. In the Mayo Clinic experience, as analyzed by
King et al.6 the 5-year recurrence-free rate was 56% for
patients resected with a 4-cm margin compared with 29% for
those resected with a 2-cm margin. We did not analyze the
length of the disease-free margins, although we tried to
maintain at least 3 cm laterally, or one nondiseased rib
vertically, as the surgical margin when possible. Note that
complete resection of tumors involving the costovertebral
junction is technically demanding, despite neoadjuvant ther-
apy, due to the neighbouring vertebral body. In our series, the
tumors invaded the costovertebral junction in 9 patients
(36%). Of these, seven patients had surgical resections: two
patients underwent laminectomy, one required vertebral re-
section, and four had complete resections. The resections
were incomplete (R1) in three patients. Nevertheless, three of
the four patients with complete resections (75%) developed
locoregional recurrence. In these patients, resection with wide
resection margins was impossible because of the site. In our
survival analysis, costovertebral junction involvement was a
significant prognostic factor. Some adjuvant radiotherapy
modifications, such as brachytherapy or the CyberKnife,
could be beneficial in these patients. These modalities have
been shown to be effective in the treatment of PNETs,
different tumors of the spine, lung cancer or tumors in other
parts of the body.13–15
In addition, whether “adjuvant” surgical resection fol-
lowing chemotherapy confers better survival is not cer-
tain.10,12 This uncertainty exists partly because almost all case
reports are for thoracic PNETs. In our series, neoadjuvant
therapy followed by the widest possible resection resulted in
less recurrence and longer survival. This conclusion has been
supported by some other studies.8,11
In addition, we found that, neoadjuvant treatment re-
sulted in a significantly better recurrence-free survival. For
these reasons, we recommend that all patients with thoracic
PNETs receive neoadjuvant treatment before planned sur-
gery. In our series, the mean regression rate was 65.4%
(range, 30–100). Given this response rate, we speculate that
a higher dose, shorter duration of chemotherapy, and more
chemotherapy courses could result in a higher response rate
and longer survival in these patients.
Primary lung PNETs without pleural or chest involve-
ment is extremely rare. We had four such patients. In patients
with pulmonary PNETs, achieving complete resection is
difficult because of probable inoculation metastases and vis-
ceral pleural invasion. The mean 2-year event-free survival
rate was 25% in these patients.
This study has certain limitations. First, despite all our
efforts and the multicenter nature of the study, the number of
patients was small, precluding subgroup analysis. Second, we
were not able to document the details of adjuvant radiother-
apy. In addition, varying neoadjuvant approaches compli-
cated the outcome assessment. For this reason, we also could
not evaluate the value of additional neoadjuvant radiotherapy
in our patients.
In conclusion, patients undergoing definitive surgery after
initial chemotherapy had a higher success frequency of complete
thoracic PNET resections and better disease-free survival. Pa-
tients who underwent the widest possible resection survived
longer, and had fewer metastases and locoregional recurrence.
Incomplete resection was found to be futile. Patients with a
tumor invading a vertebra (i.e., the costovertebral junction) had
a discouraging prognosis despite extended resection. However,
even with multimodal therapy, patients with thoracic PNETs had
an unsatisfactory survival and high recurrence rates. Further
studies are warranted to define the ideal management.
REFERENCES
1. Weiss SW, Goldblum JR. Primitive neuroectodermal tumors and related
lesions. In Weiss SW, Goldblum JR (Eds.), Soft Tissue Tumors, 4th Ed.
St Louis, MO: Mosby, 2001. Pp. 1265–1323.
2. Dehner LP. Primitive neuroectodermal tumor and Ewing’s sarcoma.
Am J Surg Pathol 1993;17:1–13.
3. Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small
cell tumor of the thoracopulmonary region in childhood: a distinctive
clinicopathologic entity of uncertain histogenesis. Cancer 1979;43:2438–2441.
4. Jurgens H, Bier V, Harms D, et al. Malignant peripheral neuroectodermal
tumors: a retrospective analysis of 42 patients. Cancer 1988;61:349–357.
5. Schulman H, Newman-Heinman N, Kurtzbart E, Maor E, Zirkin H, Laufer
L. Thoracoabdominal peripheral primitive neuroectodermal tumors in child-
hood: radiological features. Eur Radiol 2000;10:1649–1652.
6. King RM, Pairolero PC, Trastek VF, Piehler JM, Payne WS, Bernatz PE.
Primary chest wall tumors: factors affecting survival. Ann Thorac Surg 1986;
41:597–601.
7. Kahn AG, Avagnina A, Nazar J, Elsner B. Primitive neuroectodermal
tumor of the lung. Arch Pathol Lab Med 2001;125:397–399.
8. Kushner BH, Hajdu SI, Gulati SC, Erlandson RA, Exelby PR, Lieberman
Journal of Thoracic Oncology • Volume 4, Number 2, February 2009 Primitive Neuroectodermal Tumors of the Thorax
Copyright © 2009 by the International Association for the Study of Lung Cancer 191
PH. Extracranial primitive neuroectodermal tumors: the memorial Sloan–
Kettering Cancer Center experience. Cancer 1991;67:1825–1829.
9. Hage R, Duurkens VA, Seldenrijk CA, Brutel de la Rivie`re A, van
Swieten HA, van den Bosch JM. Primitive neuroectodermal tumor:
report of two cases and review of the literature. J Thorac Cardiovasc
Surg 2002;124:833–836.
10. Shamberger RC, LaQuaglia MP, Gebhardt MC, et al. Ewing sarcoma/
primitive neuroectodermal tumor of the chest wall. Impact of initial
versus delayed resection on tumor margins, survival, and use of radiation
therapy. Ann Surg 2003;238:563–568.
11. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and
etoposide to standard chemotherapy for Ewing’s sarcoma and primitive
neuroectodermal tumor of bone. N Engl J Med 2003;348:694–701.
12. Gunluoglu MZ, Kara HV, Demir A, Dincer SI. Results of multimodal
treatment of two patients with thoracic primitive neuroectodermal tumor.
Is surgery really helpful for survival? Thorac Cardiovasc Surg 2007;55:
460–461.
13. Gerszten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless
stereotactic radiosurgery for spinal lesions: clinical experience in 125
cases. Neurosurgery 2004;55:89–98.
14. Brown WT, Wu X, Wen BC, et al. Early results of CyberKnife
image-guided robotic stereotactic radiosurgery for treatment of lung
tumors. Comput Aided Surg 2007;12:253–261.
15. Gaona-Luviano P, Unda-Franco E, Gonza´lez-Jara L, Romero P, Medina-
Franco H. Primitive neuroectodermal tumor of the vagina. Gynecol
Oncol 2003;91:456–458.
Demir et al. Journal of Thoracic Oncology • Volume 4, Number 2, February 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer192
